AbbVie (ABBV) stock has been in focus after a series of recent drug approvals, including European clearance for Aquipta in acute migraine, an expanded EU label for Venclyxto in first-line CLL, and FDA approval of Decnupaz for BPDCN.

Those approvals have arrived alongside firm share price momentum, with AbbVie’s 1 month share price return of 10.83% and 7 day share price return of 4.37% standing against a slightly weaker 90 day share price return and strong 5 year total shareholder return of 137.48%. This suggests longer term holders have already seen substantial value created while shorter term sentiment is improving.

If these drug approvals have you thinking about what else might be moving in healthcare, use this as a starting point to check out 39 healthcare AI stocks

With AbbVie’s shares up in the short term, a long history of strong total returns and various valuation tools pointing to possible upside, the key question is simple: is there still value on the table or is the market already baking in the next leg of growth?

Preferred P/E of 111.7x: Is It Justified?

On a simple P/E lens, AbbVie looks expensive, with a P/E of 111.7x that sits well above many investors’ comfort zone at a last close of $227.23.

The P/E ratio compares the current share price to earnings per share and is a common yardstick for mature, profitable companies like large biopharma groups. A higher P/E usually means the market is paying more today for each dollar of earnings, often where investors expect earnings to be stronger in future or are willing to pay up for the business profile.

For AbbVie, the current P/E of 111.7x is far higher than both the US Biotechs industry average of 16.6x and the peer average of 20.6x. It is also well above an estimated fair P/E of 37.3x that some models suggest the market could ultimately gravitate toward if expectations cool or earnings trends change.

Result: Price-to-Earnings of 111.7x (OVERVALUED)

However, there are clear risks, including AbbVie’s very high P/E of 111.7x and a 90 day share price return that is slightly down at 1.25%.

Another View: DCF Points the Other Way

The P/E picture makes AbbVie look expensive, but our DCF model points to something very different. With the stock at $227.23 and an estimated future cash flow value of $439.27, AbbVie is flagged as trading about 48.3% below that fair value estimate. This raises the question of which signal may be more informative: earnings multiples or cash flow value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AbbVie for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation models and sentiment, do you want to wait and react or quickly weigh both sides and decide where you stand? Start by weighing 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If AbbVie has your attention, do not stop here. Broaden your watchlist with a few focused stock ideas that could sharpen how you think about opportunities.

• Target quality at a discount by reviewing companies flagged in the 49 high quality undervalued stocks and see which ones line up with your own price expectations.
• Strengthen your income stream by checking out the 9 dividend fortresses and compare yields with balance sheet support behind them.
• Prioritize resilience by scanning the 64 resilient stocks with low risk scores and spot stocks that may help steady your overall portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.